Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Altimmune (ALT) over the last 7 years, with Q3 2018 value amounting to $173952.0.

  • Altimmune's Current Deferred Revenue rose 78063.59% to $173952.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $173952.0, marking a year-over-year increase of 78063.59%. This contributed to the annual value of $19753.0 for FY2017, which is 0.0% changed from last year.
  • Latest data reveals that Altimmune reported Current Deferred Revenue of $173952.0 as of Q3 2018, which was up 78063.59% from $172414.0 recorded in Q2 2018.
  • Altimmune's 5-year Current Deferred Revenue high stood at $173952.0 for Q3 2018, and its period low was $19753.0 during Q4 2016.
  • Over the past 4 years, Altimmune's median Current Deferred Revenue value was $38503.0 (recorded in 2017), while the average stood at $68111.5.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 9287.96% in 2014, then soared by 78063.59% in 2018.
  • Over the past 4 years, Altimmune's Current Deferred Revenue (Quarter) stood at $62261.0 in 2014, then tumbled by 68.27% to $19753.0 in 2016, then changed by 0.0% to $19753.0 in 2017, then soared by 780.64% to $173952.0 in 2018.
  • Its Current Deferred Revenue was $173952.0 in Q3 2018, compared to $172414.0 in Q2 2018 and $44753.0 in Q1 2018.